Take heed to this text
Titan Medical (Nasdaq:TMDI) introduced right now that it plans to evaluation and consider strategic options to unlock shareholder worth.
Toronto-based Titan develops single-access robotic-assisted surgical procedure expertise. It consulted with monetary and authorized advisors to find out that the evaluation is within the firm’s and stakeholders’ greatest curiosity.
In line with a information launch, Titan’s board plans to think about a full vary of strategic options. Which will embrace a company sale, merger or different enterprise mixture. It might additionally result in a sale of all or a portion of its property, strategic funding or different important transaction.
Titan Medical earlier this month introduced a plan to carry a digital shareholder assembly on Jan. 12, 2023. The purpose is to hunt approval for a share consolidation plan to keep up the corporate’s Nasdaq itemizing.
As a part of the strategic evaluation, Titan engaged Raymond James as a monetary advisor. Raymond James’ function contains advising the corporate within the evaluation and analyzing strategic options.
No ensures out of the evaluation
Titan didn’t set a timetable for the completion of this course of. The corporate mentioned it doesn’t intend to supply updates on developments till it executes a definitive settlement. An exception might come ought to the board decide that an replace is suitable or required.
The corporate intends to guage all choices pretty to maximise shareholder worth. Nonetheless, it mentioned it couldn’t guarantee that the method will end in any transaction. As well as, ought to the corporate undertake a transaction, it has no ensures relating to its phrases or timing.
“Our administration workforce is totally aligned with the board’s choice to discover choices to maximise shareholder worth,” mentioned Titan President and CEO Cary Vance. “We consider it’s prudent to undertake a evaluation of our strategic choices to find out the most effective path ahead to comprehend the worth of our improvements in single-access robotic-assisted applied sciences to maximise shareholder worth. Our Board and administration workforce stay dedicated to our technique of offering sufferers, surgeons and hospitals with an revolutionary, improved surgical expertise.”
Might prior relationships come into play?
Titan has a longstanding relationship with medtech large Medtronic, together with a variety of buy orders, milestone funds and extra. That relationship might be value maintaining a tally of as Titan’s evaluation course of performs out.
In September, Titan and Medtronic entered right into a growth deal on surgical robots. The settlement constructed on a 2020 growth and license deal. Titan achieved all three milestones within the settlement, together with elevating $18 million in capital in October 2020. In Might, Titan signed a $2.6 million buy order from Medtronic to supply devices and cameras for preclinical actions.
“Medtronic’s curiosity has been in Titan’s capacity to innovate,” Vance informed MassDevice in October. “That was the genesis of the association we had about two-and-a-half years in the past after we have been requested to develop some expertise for them.”
Editor’s Observe: This text first appeared on sister web site MassDevice and was republished with permission.